SchrodingerSDGR
About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Employees: 787
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $5M
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
10% more capital invested
Capital invested by funds: $1.19B [Q4 2024] → $1.31B (+$117M) [Q1 2025]
6.61% more ownership
Funds ownership: 97.19% [Q4 2024] → 103.8% (+6.61%) [Q1 2025]
2% more funds holding
Funds holding: 210 [Q4 2024] → 214 (+4) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Keybanc Scott Schoenhaus | 56%upside $32 | Overweight Maintained | 16 Apr 2025 |
Piper Sandler Joseph Catanzaro | 119%upside $45 | Overweight Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 10 articles about SDGR published over the past 30 days









